# US 2026/0183310 A1 · Neurosteroid derivative solid dispersion, and preparation method and use thereof, and therapeutic drug for central nervous system disorder-related condition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0183310 A1
- Document ID: US20260183310A1
- Status: Published application
- Kind: A1
- Application number: 19/443,275
- Filed: 2026-01-08
- Published: 2026-07-02
- Earliest claimed: 2024-12-06
- Assignees: Hunan Mingrui Pharmaceutical Co., Ltd.
- Applicants: Hunan Mingrui Pharmaceutical Co., Ltd
- Inventors: Zhen CHANG; Ning LV; Haijian WANG; Bin KUANG; Dongdong WANG
- Web page: https://patentgrep.com/patent/US20260183310A1

## CPC

- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 9/146: {with organic macromolecular compounds}
- A61K 9/1641: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers}
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers}
- A61K 9/2045: {Polyamides; Polyaminoacids, e.g. polylysine}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2095: {Tabletting processes}
- A61K 9/2893: {Tablet coating processes (mechanical aspects A61J3/06)}
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61P 25/00: Drugs for disorders of the nervous system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are a neurosteroid derivative solid dispersion, and a preparation method and use, and a drug containing a hot-melt extruded solid dispersion. A raw material mixture is subjected to melt extrusion at 125° C. to 160° C. to obtain the neurosteroid derivative solid dispersion, where the raw material mixture includes an active ingredient, a plasticizer and a carrier material, a mass ratio of the three being in a range of 10:1-15:10-90; the active ingredient includes at least one selected from the group consisting of a neurosteroid derivative (having a structure represented by formula 1), and an isomer, a solvate and a pharmaceutically acceptable salt thereof; the plasticizer is one or more selected from the group consisting of polyethylene glycol, poloxamer and Tween, the polyethylene glycol having an average molecular weight of less than 6000; and the active ingredient is present in an amorphous state.

## Claims

### Claim 1

A method for preparing a neurosteroid derivative solid dispersion, comprising:
subjecting a raw material mixture to melt extrusion at a temperature of 125° C. to 160° C. to obtain the neurosteroid derivative solid dispersion,
wherein the raw material mixture comprises an active ingredient, a plasticizer and a carrier material, a mass ratio of the active ingredient, the plasticizer and the carrier material being in a range of 10:1-15:10-90;
the active ingredient comprises at least one selected from the group consisting of a neurosteroid derivative, and an isomer, a solvate and a pharmaceutically acceptable salt thereof, the neurosteroid derivative having a structure represented by formula 1:
wherein R1 in formula 1 is one selected from the group consisting of —H and C1-C12 alkyl; and R2 is one selected from the group consisting of R—(C═O)—, R—(C═S)—, R—(S═O)—, R—(SO2)— and R—CH(OH)—, R being one selected from the group consisting of —H, C1-C6 alkyl, C2-C6 alkenyl and C2-C6 alkynyl;
the plasticizer is one or more selected from the group consisting of polyethylene glycol, poloxamer and Tween, the polyethylene glycol having an average molecular weight of less than 6000; and
the active ingredient in the neurosteroid derivative solid dispersion is present in an amorphous state.

### Claim 2 (depends on 1)

The method of claim 1, wherein the R1 is —H, the R2 is R—(C═O)—, and the R is C1-C3 alkyl; and
the neurosteroid derivative has a structure represented by formula 2:

### Claim 3 (depends on 1)

The method of claim 1, wherein the polyethylene glycol comprises one or more selected from the group consisting of PEG3350, PEG400 and PEG4000; the poloxamer comprises poloxamer 188 and/or poloxamer 407; and the Tween comprises one or more selected from the group consisting of Tween 80, Tween 20 and Tween 40; and
the carrier material comprises one or more selected from the group consisting of copovidone, a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, lauryl polyethylene glycol glyceride, polyvinyl alcohol, polyvinylpyrrolidone, polyoxyethylene, polylactic acid, polyglycolic acid, a lactic acid-glycolic acid copolymer, an ethylene-vinyl acetate copolymer, an acrylic resin, a cellulose derivative, starch and a starch derivative.

### Claim 4 (depends on 3)

The method of claim 3, wherein the copovidone comprises PVP-VA64.

### Claim 5 (depends on 3)

The method of claim 3, wherein the raw material mixture consists of the active ingredient, the polyethylene glycol and the copovidone; and
the polyethylene glycol is PEG3350, and the copovidone is PVP-VA64.

### Claim 6 (depends on 3)

The method of claim 3, wherein the raw material mixture consists of the active ingredient, the polyethylene glycol and the polyethylene caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer; and
the polyethylene glycol is PEG3350.

### Claim 7 (depends on 3)

The method of claim 3, wherein the raw material mixture consists of the active ingredient, the poloxamer and the polyethylene caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer; and
the poloxamer is poloxamer 188.

### Claim 8 (depends on 3)

The method of claim 3, wherein the raw material mixture consists of the active ingredient, the Tween and the copovidone; and
the Tween is the Tween 80, and the copovidone is PVP-VA64.

### Claim 9 (depends on 1)

The method of claim 1, wherein the melt extrusion is performed in a twin-screw hot-melt extruder, with a screw rotational speed of the twin-screw hot-melt extruder being in a range of 50 rpm to 200 rpm.

### Claim 10 (depends on 9)

The method of claim 9, wherein a feeding rate of the raw material mixture is in a range of 5 g/min to 10 g/min.

### Claim 11 (depends on 1)

A neurosteroid derivative solid dispersion prepared by the method of claim 1.

### Claim 12 (depends on 11)

A process for treating a central nervous system disorder-related condition, comprising administrating the neurosteroid derivative solid dispersion of claim 11 to a subject in need thereof.

### Claim 13 (depends on 12)

The process of claim 12, wherein the central nervous system disorder-related condition comprises one selected from the group consisting of postpartum depression, clinical depression, atypical depression, major depressive disorder, bipolar affective disorder, mood disorder, anxiety, post-traumatic stress disorder, premenstrual dysphoric disorder, premenstrual syndrome, generalized anxiety disorder, seasonal affective disorder, social anxiety disorder, memory loss, stress intolerance, type C Niemann-Pick's disease or related neurological or physical symptoms, epilepsy, essential tremor, epileptiform disorder, N-methyl-d-aspartic acid (NMDA) hypofunction, migraine, status epilepticus, sleep disorder, fragile X syndrome, 5α-reductase inhibitor-induced depression, PCDH19-related epilepsy in pediatric females, sexual dysfunction, cognitive disorder, Parkinson's disease and Alzheimer's disease.

### Claim 14 (depends on 11)

A therapeutic drug for a central nervous system disorder-related condition, wherein raw materials for preparation of the drug comprise the neurosteroid derivative solid dispersion of claim 11 and a pharmaceutically acceptable excipient.

### Claim 15 (depends on 14)

The therapeutic drug for the central nervous system disorder-related condition of claim 14, wherein the pharmaceutically acceptable excipient comprises one or more selected from the group consisting of a diluent, a disintegrant, a glidant and a lubricant;
the diluent comprises one or more selected from the group consisting of lactose, microcrystalline cellulose, anhydrous calcium hydrogen phosphate and sodium chloride;
the disintegrant comprises one or more selected from the group consisting of a low-substituted hydroxypropyl cellulose, sodium carboxymethyl starch and crospovidone;
the glidant comprises colloidal silicon dioxide; and
the lubricant comprises at least one selected from the group consisting of magnesium stearate and sodium stearyl fumarate.

### Claim 16 (depends on 14)

The therapeutic drug for the central nervous system disorder-related condition of claim 14, wherein the therapeutic drug for the central nervous system disorder-related condition is an oral drug; and
a dosage form of the oral drug comprises one selected from the group consisting of a tablet, a capsule and a granule.

### Claim 17 (depends on 16)

The therapeutic drug for the central nervous system disorder-related condition of claim 16, wherein the tablet is a film-coated tablet; and
the film-coated tablet is prepared by a process comprising the following steps:
mixing the neurosteroid derivative solid dispersion, a diluent, a disintegrant, a glidant and a lubricant, subjecting a resulting mixture to compression to obtain the tablet, and then subjecting the tablet to film coating with a gastric-soluble coating premix to obtain the film-coated tablet.

### Claim 18 (depends on 17)

The therapeutic drug for the central nervous system disorder-related condition of claim 17, wherein a mass ratio of the neurosteroid derivative solid dispersion, the diluent, the disintegrant, the glidant and the lubricant is in a range of 65-95:45-60:8-12:3-5:0.5-1.5.

### Claim 19 (depends on 17)

The therapeutic drug for the central nervous system disorder-related condition of claim 17, wherein a tablet weight during the compression is in a range of 225 mg to 400 mg.

### Claim 20 (depends on 17)

The therapeutic drug for the central nervous system disorder-related condition of claim 17, wherein a coating weight gain after the film coating is in a range of 3% to 5%.
